Adapted J6/JFH1-based hepatitis C virus recombinants with genotype-specific NS4A show similar efficacies against lead protease inhibitors, alpha interferon, and a putative NS4A inhibitor

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 12, 2013, Pages 6034-6049

  Gottwein, Judith M ^a,b   Jensen, Sanne B ^a,b   Serre, Stéphanie B N ^a,b   Ghanem, Lubna ^a,b   Scheel, Troels K H ^a,b   Jensen, Tanja B ^a,b   Krarup, Henrik ^c   Uzcategui, Nathalie ^a,b   Mikkelsen, Lotte S ^a,b   Bukh, Jens ^a,b  

^a Mental Health Center Glostrup   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACH 806; ALANINE; ALPHA INTERFERON; ALPHA2B INTERFERON; AMINO ACID; ANTIVIRUS AGENT; BOCEPREVIR; DANOPREVIR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; NONSTRUCTURAL PROTEIN 4A INHIBITOR; PEPTIDE HYDROLASE INHIBITOR; PHENYLALANINE; PROTEINASE INHIBITOR; SERINE; SIMEPREVIR; TELAPREVIR; UNCLASSIFIED DRUG; VALINE; VANIPREVIR; 1-(4-PENTYLOXY-3-TRIFLUOROMETHYLPHENYL)-3-(PYRIDINE-3-CARBONYL)THIOUREA; CARRIER PROTEIN; NS3 PROTEIN, HEPATITIS C VIRUS; NS4A COFACTOR PEPTIDE, HEPATITIS C VIRUS; PHENYLTHIOUREA; VIRUS PROTEIN;

AMINO ACID SUBSTITUTION; ANTIBODY TITER; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; GENE MUTATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; LIFE CYCLE; LONG TERM CARE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; VIROGENESIS; VIRUS CULTURE; VIRUS ISOLATION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION; GENETIC REASSORTMENT; GENETIC RECOMBINATION; GENETICS; HEPACIVIRUS; LIVER CELL; METABOLISM; TUMOR CELL LINE; VIROLOGY;

ANTIVIRAL AGENTS; CARRIER PROTEINS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; GENE EXPRESSION; GENOTYPE; HEPACIVIRUS; HEPATOCYTES; HUMANS; INTERFERON-ALPHA; PHENYLTHIOUREA; PROTEASE INHIBITORS; REASSORTANT VIRUSES; RECOMBINATION, GENETIC; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84887485664     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01176-13     Document Type: Article

References (52)

1. Gottwein JM, Bukh J. 2008. Cutting the gordian knot-development and biological relevance of hepatitis C virus cell culture systems. Adv. Virus Res. 71:51-133.
2. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Halfon P, Inchauspe G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin IT, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A. 2005. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42:962-973.
3. Antaki N, Craxi A, Kamal S, Moucari R, Van der Merwe S, Haffar S, Gadano A, Zein N, Lai CL, Pawlotsky JM, Heathcote EJ, Dusheiko G, Marcellin P. 2010. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int. 30:342-355.
4. Dustin LB, Rice CM. 2007. Flying under the radar: the immunobiology of hepatitis C. Annu. Rev. Immunol. 25:71-99.
5. Beran RK, Lindenbach BD, Pyle AM. 2009. The NS4A protein of hepatitisCvirus promotes RNA-coupled ATP hydrolysis by the NS3 helicase. J. Virol. 83:3268-3275.
6. Lindenbach BD, Pragai BM, Montserret R, Beran RK, Pyle AM, Penin F, Rice CM. 2007. The C terminus of hepatitis C virus NS4A encodes an electrostatic switch that regulates NS5A hyperphosphorylation and viral replication. J. Virol. 81:8905-8918.
7. Shiryaev SA, Chernov AV, Shiryaeva TN, Aleshin AE, Strongin AY. 2011. The acidic sequence of the NS4A cofactor regulates ATP hydrolysis by the HCV NS3 helicase. Arch. Virol. 156:313-318.
8. Phan T, Beran RK, Peters C, Lorenz IC, Lindenbach BD. 2009. Hepatitis C virus NS2 protein contributes to virus particle assembly via opposing epistatic interactions with the E1-E2 glycoprotein and NS3-NS4A enzyme complexes. J. Virol. 83:8379-8395.
9. Stapleford KA, Lindenbach BD. 2011. Hepatitis C virus NS2 coordinates virus particle assembly through physical interactions with the E1-E2 glycoprotein and NS3-NS4A enzyme complexes. J. Virol. 85:1706-1717.
10. Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM. 2012. Antiviral strategies in hepatitis C virus infection. J. Hepatol. 56(Suppl 1):S88-S100.
11. Yang W, Zhao Y, Fabrycki J, Hou X, Nie X, Sanchez A, Phadke A, Deshpande M, Agarwal A, Huang M. 2008. Selection of replicon variants resistant to ACH-806, a novel hepatitis C virus inhibitor with no crossresistance to NS3 protease and NS5B polymerase inhibitors. Antimicrob. Agents Chemother. 52:2043-2052.
12. Wyles DL, Kaihara KA, Schooley RT. 2008. Synergy of a hepatitis C virus (HCV) NS4A antagonist in combination with HCV protease and polymerase inhibitors. Antimicrob. Agents Chemother. 52:1862-1864.
13. Yang W, Sun Y, Hou X, Zhao Y, Fabrycki J, Chen D, Wang X, Agarwal A, Phadke A, Deshpande M, Huang M. 2013. ACH-806, an NS4A antagonist, inhibits hepatitis C virus replication by altering the composition of viral replication complexes. Antimicrob. Agents Chemother. 57: 3168-3177.
14. Gottwein JM, Scheel TK, Jensen TB, Ghanem L, Bukh J. 2011. Differential efficacy of protease inhibitors againstHCVgenotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. Gastroenterology 141:1067-1079.
15. Imhof I, Simmonds P. 2010. Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6. J. Virol. 84:4597-4610.
16. Imhof I, Simmonds P. 2011. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). Hepatology 53:1090-1099.
17. Yi M, Villanueva RA, Thomas DL, Wakita T, Lemon SM. 2006. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc. Natl. Acad. Sci. U. S. A. 103:2310-2315.
18. Pietschmann T, Zayas M, Meuleman P, Long G, Appel N, Koutsoudakis G, Kallis S, Leroux-Roels G, Lohmann V, Bartenschlager R. 2009. Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations. PLoS Pathog. 5:e1000475. doi:10.1371/journal. ppat.1000475.
19. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M, Bartenschlager R, Liang TJ. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796.
20. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM. 2005. Complete replication of hepatitis C virus in cell culture. Science 309:623-626.
21. Yanagi M, Purcell RH, Emerson SU, Bukh J. 1997. Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc. Natl. Acad. Sci. U. S. A. 94:8738-8743.
22. Sakai A, Takikawa S, Thimme R, Meunier JC, Spangenberg HC, Govindarajan S, Farci P, Emerson SU, Chisari FV, Purcell RH, Bukh J. 2007. In vivo study of the HC-TN strain of hepatitis C virus recovered from a patient with fulminant hepatitis: RNA transcripts of a molecular clone (pHC-TN) are infectious in chimpanzees but not in Huh7.5 cells. J. Virol. 81:7208-7219.
23. Yanagi M, St Claire M, Shapiro M, Emerson SU, Purcell RH, Bukh J. 1998. Transcripts of a chimeric cDNA clone of hepatitis C virus genotype 1b are infectious in vivo. Virology 244:161-172.
24. Yanagi M, Purcell RH, Emerson SU, Bukh J. 1999. Hepatitis C virus: an infectious molecular clone of a second major genotype (2a) and lack of viability of intertypic 1a and 2a chimeras. Virology 262:250-263.
25. Gottwein JM, Scheel TK, Callendret B, Li YP, Eccleston HB, Engle RE, Govindarajan S, Satterfield W, Purcell RH, Walker CM, Bukh J. 2010. Novel infectious cDNA clones of hepatitisCvirus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies. J. Virol. 84:5277-5293.
26. Bukh J, Meuleman P, Tellier R, Engle RE, Feinstone SM, Eder G, Satterfield WC, Govindarajan S, Krawczynski K, Miller RH, Leroux- Roels G, Purcell RH. 2010. Challenge pools of hepatitis C virus genotypes 1-6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models. J. Infect. Dis. 201:1381-1389.
27. Li YP, Ramirez S, Jensen SB, Purcell RH, Gottwein JM, Bukh J. 2012. Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system. Proc. Natl. Acad. Sci. U. S. A. 109:19757-19762.
28. Li YP, Ramirez S, Gottwein JM, Scheel TK, Mikkelsen L, Purcell RH, Bukh J. 2012. Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains. Proc. Natl. Acad. Sci. U. S. A. 109:E1101-E1110.
29. Gottwein JM, Scheel TK, Hoegh AM, Lademann JB, Eugen-Olsen J, Lisby G, Bukh J. 2007. Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses. Gastroenterology 133:1614-1626.
30. Blight KJ, McKeating JA, Rice CM. 2002. Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J. Virol. 76: 13001-13014.
31. Gottwein JM, Scheel TK, Jensen TB, Lademann JB, Prentoe JC, Knudsen ML, Hoegh AM, Bukh J. 2009. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 49:364-377.
32. Russell RS, Meunier JC, Takikawa S, Faulk K, Engle RE, Bukh J, Purcell RH, Emerson SU. 2008. Advantages of a single-cycle production assay to study cell culture-adaptive mutations of hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 105:4370-4375.
33. Date T, Kato T, Kato J, Takahashi H, Morikawa K, Akazawa D, Murayama A, Tanaka-Kaneko K, Sata T, Tanaka Y, Mizokami M, Wakita T. 2012. Novel cell culture-adapted genotype 2a hepatitis C virus infectious clone. J. Virol. 86:10805-10820.
34. Ramirez S, Li YP, Jensen SB, Pedersen J, Gottwein JM, Bukh J. 2013. Highly efficient infectious cell culture of three HCV genotype 2b strains and sensitivity to lead protease, NS5A, and polymerase inhibitors. Hepatology doi:10.1002/hep.26660.
35. Li YP, Ramirez S, Gottwein JM, Bukh J. 2011. Non-genotype-specific role of the hepatitis C virus 5= untranslated region in virus production and in inhibition by interferon. Virology 421:222-234.
36. Li YP, Gottwein JM, Scheel TK, Jensen TB, Bukh J. 2011. MicroRNA- 122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5= UTR. Proc. Natl. Acad. Sci. U. S. A. 108:4991-4996.
37. Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, Steinmann E, Abid K, Negro F, Dreux M, Cosset FL, Bartenschlager R. 2006. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl. Acad. Sci. U. S. A. 103:7408-7413.
38. Yi M, Lemon SM. 2004. Adaptive mutations producing efficient replication of genotype 1a hepatitis C virus RNA in normal Huh7 cells. J. Virol. 78:7904-7915.
39. Scheel TK, Gottwein JM, Jensen TB, Prentoe JC, Hoegh AM, Alter HJ, Eugen-Olsen J, Bukh J. 2008. Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. Proc. Natl. Acad. Sci. U. S. A. 105:997-1002.
40. Jensen TB, Gottwein JM, Scheel TK, Hoegh AM, Eugen-Olsen J, Bukh J. 2008. Highly efficient JFH1-based cell-culture system for hepatitis C virus genotype 5a: failure of homologous neutralizing-antibody treatment to control infection. J. Infect. Dis. 198:1756-1765.
41. Scheel TK, Gottwein JM, Carlsen TH, Li YP, Jensen TB, Spengler U, Weis N, Bukh J. 2011. Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS2 by using previously identified mutations. J. Virol. 85:2891-2906.
42. Gottwein JM, Jensen TB, Mathiesen CK, Meuleman P, Serre SB, Lademann JB, Ghanem L, Scheel TK, Leroux-Roels G, Bukh J. 2011. Development and application of hepatitis C reporter viruses with genotype 1 to 7 core-nonstructural protein 2 (NS2) expressing fluorescent proteins or luciferase in modified JFH1 NS5A. J. Virol. 85:8913-8928.
43. Scheel TK, Gottwein JM, Mikkelsen LS, Jensen TB, Bukh J. 2011. RecombinantHCVvariants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-alpha. Gastroenterology 140:1032-1042.
44. Murayama A, Kato T, Akazawa D, Sugiyama N, Date T, Masaki T, Nakamoto S, Tanaka Y, Mizokami M, Yokosuka O, Nomoto A, Wakita T. 2012. Production of infectious chimeric hepatitis C virus genotype 2b harboring minimal regions of JFH-1. J. Virol. 86:2143-2152.
45. Gottwein JM, Jensen SB, Li YP, Ghanem L, Scheel TK, Serre SB, Mikkelsen L, Bukh J. 2013. Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses. Antimicrob. Agents Chemother. 57:1291-1303.
46. Patargias G, Zitzmann N, Dwek R, Fischer WB. 2006. Protein-protein interactions: modeling the hepatitis C virus ion channel p7. J. Med. Chem. 49:648-655.
47. Jirasko V, Montserret R, Lee JY, Gouttenoire J, Moradpour D, Penin F, Bartenschlager R. 2010. Structural and functional studies of nonstructural protein 2 of the hepatitis C virus reveal its key role as organizer of virion assembly. PLoS Pathog. 6:e1001233. doi:10.1371/journal.ppat.1001233.
48. Steinmann E, Penin F, Kallis S, Patel AH, Bartenschlager R, Pietschmann T. 2007. Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. PLoS Pathog. 3:e103. doi:10.1371/journal .ppat.0030103.
49. Jones CT, Murray CL, Eastman DK, Tassello J, Rice CM. 2007. Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. J. Virol. 81:8374-8383.
50. Ma Y, Anantpadma M, Timpe JM, Shanmugam S, Singh SM, Lemon SM, Yi M. 2011. Hepatitis C virus NS2 protein serves as a scaffold for virus assembly by interacting with both structural and nonstructural proteins. J. Virol. 85:86-97.
51. Brass V, Berke JM, Montserret R, Blum HE, Penin F, Moradpour D. 2008. Structural determinants for membrane association and dynamic organization of the hepatitis C virus NS3-4A complex. Proc. Natl. Acad. Sci. U. S. A. 105:14545-14550.
52. Sun JH, O'Boyle IDR, Zhang Y, Wang C, Nower P, Valera L, Roberts S, Nettles RE, Fridell RA, Gao M. 2012. Impact of a baseline polymorphism on the emergence of resistance to the hepatitis C virus nonstructural protein 5A replication complex inhibitor, BMS-790052. Hepatology 55:1692-1699.